Index

A CD4+ cell counts , 26 Acquired immunodefi ciency syndrome classic primary effusion lymphoma , 31, 32 (AIDS) , 54Ð55. See also classi fi cation , 24, 25 AIDS-related lymphomas (ARL) description , 24 Activated B-cell (ABC) lymphomas , 174, 175 diffuse large B-cell lymphoma , 28Ð29 Adaptive immune responses , 11, 12 epidemiology , 25 Adult T-cell lymphoma (ATLL) extracavitary (solid) primary effusion aggressive , 145 lymphoma , 32 clinical and molecular prognostic Hodgkin lymphoma , 33Ð34 factors , 145 low-grade non-Hodgkin lymphoma , 33 description , 144 mature T-cell non-Hodgkin and zidovudine, use of , 228 lymphoma , 33 KW-0761 , 228 plasmablastic lymphoma , 29Ð31 LMB-2 agent , 221 vs. plasmacellular differentiation , 26, 27 Shimoyama classi fi cation , 144 polymorphic lymphoproliferative Aggressive lymphomas disorder , 32Ð33 B-cell receptor signaling inhibitors Allogeneic HSCT , 272Ð273 Bruton tyrosine kinase inhibitors , Allogeneic transplant, PTCL 177Ð178 graft versus lymphoma effect , 288 PKC inhibitors , 178 heterogeneous conditioning , 289Ð290 Syk inhibitors , 177 myeloablative conditioning , 288Ð289 heat shock protein inhibitors , 179 prospective analysis , 290Ð291 histone deacetylase inhibitors , 180Ð181 Anaplastic large cell lymphoma (ALCL) , immunomodulatory drugs , 181 33, 34, 145Ð146 mammalian target of rapamycin Anaplastic variant , 28 inhibitors , 179Ð180 Angioimmunoblastic T-cell lymphoma monoclonal , 181 (AITL) , 144 anti-CD20 , 182 Ann Arbor lymphoma staging system , targeted , 182Ð183 101, 102 PET-CT , 175Ð176 Anti-CD22 proteasome inhibitors , 176Ð177 immunotoxins treatments , 176 BL-22 , 200 Warburg effect , 175 , 200Ð201 AIDS-related lymphomas (ARL). See also monoclonal antibodies HIV-associated lymphomas , 199Ð200 Burkitt lymphoma , 26, 28 , 200

P.J. Quesenberry and J.J. Castillo (eds.), Non-Hodgkin Lymphoma: 295 Prognostic Factors and Targets, Drug Discovery and Development, DOI 10.1007/978-1-4614-5851-7, © Springer Science+Business Media New York 2013 296 Index

Anti-CD19 monoclonal antibodies CUP trial , 249 , 205 cyclophosphamide/TBI regimen , 248 hBU12-vcMMAE , 205 front-line treatment , 248Ð249 XmAb5574 , 206 randomized trials , 249Ð252 Anti-CD20 monoclonal antibodies , 182, 192 mantle cell lymphoma , 255Ð256 development , 192 peripheral T-cell lymphomas second-generation salvage studies , 258, 260 , 194Ð196 up-front studies , 258, 259 , 197 Autologous HSCT , 269, 271Ð272 , 196 Autologous transplant, PTCL small modular immunopharmaceuticals , 199 in salvage setting , 282Ð283 third-generation in upfront setting , 283Ð287 AME133v , 198 AME-133v , 198 GA-101 , 197Ð198 B PRO131921 , 198 B-cell lymphoma 6 (BCL-6) expression, 40Ð41 Anti-CD37 monoclonal antibodies , 204 B-cell lymphomas (BCL) Anti-CD40 monoclonal antibodies CD20 , 93, 94 (SGN-40) , 202Ð203 Em -myc model , 90 (HCD122) , 202 prognostic factors XmAbCD40 , 203 Ann Arbor lymphoma staging Anti-CD74 monoclonal antibodies , 201Ð202 system , 101, 102 Anti-CD80 monoclonal antibodies , 203Ð204 B lymphoblastic lymphoma , 103 Antigen-driven lymphomagenesis Burkitt lymphoma , 119Ð121 B-cell lymphoproliferation , 64 chronic lymphocytic leukemia/small C. psittaci , 66Ð68 lymphocytic lymphoma

Hashimoto thyroiditis , 73 b2 microglobulin , 107 hepatitis C virus , 68Ð69 clinical features , 105Ð107 H. pylori , 65Ð66 cytogenetic abnormalities , 107 , 69Ð71 description , 104 Sjogren syndrome , 71Ð73 histological features , 104 systemic lupus eryhtematosus , 71 immunophenotypical markers , Anti-human leukocyte antigen-DR 104Ð105 (HLA-DR) , 201 lymphocyte doubling time , 106 Anti- monoclonal antibodies molecular abnormalities , 107 , 207Ð208 oncogenetic abnormalities , 107 , 208 serum CD23 level , 106, 107 , 201 diffuse large B-cell lymphoma , ARL. See AIDS-related lymphomas (ARL) 121Ð127 ATLL. See Adult T-cell lymphoma (ATLL) features , 127Ð128 Autologous hematopoietic stem cell transplantation clinical features , 113Ð114 Burkitt lymphoma , 256Ð257 cytogenetic abnormalities , 114 diffuse large B-cell lymphoma description , 111 by age groups , 253, 254 histological features , 111Ð112 chemosensitive disease , 254 immunophenotypical features , 112 overall and event-free survival , 253Ð254 incidence , 111 prognostic scores , 252 on left hematoxylin and eosin relapsed and refractory disease , 255 stained slide , 112, 113 regimen , 253 oncogenetic abnormalities , 114 enteropathy-associated T-cell lymphoma , transformation of , 114Ð115 261Ð262 heterogenous group , 101 follicular lymphoma International Prognostic Index, 102Ð103 Index 297

lymphoplasmacytic lymphoma , 118Ð119 C mantle cell lymphoma CAL-101 , 226 clinical features , 110Ð111 Cancer stem cells cytogenetic abnormalities , 109Ð110 acute myeloid leukemia , 5Ð7 description , 107 chronic myelogenous leukemia , 3, 7, 8 histopathological features , 108 clonogenic assays , 5 immunophenotypic features , concepts , 4 108Ð109 evolution of , 8 oncogenetic abnormalities , 109Ð110 imatinib therapy , 3, 7 peripheral blood involvement , markers , 5, 6 108, 109 plating ef fi ciency , 4 p53 expression by blastoid variant , validity of , 6 109, 110 xenogeneic models , 6, 7 marginal zone type lymphomas Central nervous system lymphoma, stem marginal zone type lymphomas: cell transplantation , 242 extranodal , 115Ð116 Centroblastic variant , 28, 29 marginal zone type lymphomas: Chlamydia psittaci , 66Ð68 nodal , 116 CHOP (cyclophosphamide, , marginal zone type lymphomas: vincristine, and prednisone) , splenic , 117 216Ð219. See also T-cell rituximab mechanism of action , 92 lymphomas B-cell receptor signaling inhibitors Chronic lymphocytic leukemia/small Bruton tyrosine kinase inhibitors , 177Ð178 lymphocytic lymphoma PKC inhibitors , 178 (CLL/SLL)

Syk inhibitors , 177 b 2 microglobulin , 107 Belinostat , 224 clinical features , 105Ð107 Binet staging system , 105, 106 cytogenetic abnormalities , 107 Bispeci fi c T cell engagers (BiTE¨) , 205 description , 104 BL-22 immunotoxin , 200 histological features , 104 Blinatumomab , 183, 205 immunophenotypical markers , B lymphoblastic lymphoma , 103 104Ð105 B lymphocytes , 14Ð16 lymphocyte doubling time , 106 , 207, 226 molecular abnormalities , 107 Bruton tyrosine kinase inhibitors , 177Ð178 oncogenetic abnormalities , 107 Burkitt/Burkitt-like lymphoma serum CD23 level , 106, 107 description , 159Ð160 serum thymidine kinase , 107 natural history and clinical presentation , 160 Chronic myelogenous leukemia (CML) , post-HAART era , 160 3, 7, 8, 173Ð174 pre-HAART era , 160 Classical Hodgkin lymphoma (CHL), treatment of HIV-associated , 160 EBV , 51Ð53 Burkitt lymphoma (BL) c-MYC expression , 41 autologous hematopoietic stem cell , 207 transplantation , 256Ð257 Congenital immunode fi ciency-related Epstein-Barr virus , 49Ð51 lymphoproliferation , 54 HIV lymphomagenesis , 26, 28 Cotrimoxazol , 274 intra-abdominal tumor , 26, 28 Cyclophosphamide , 274 prognostic factors Cyclosporine , 225, 230 clinical aspects , 120Ð121 cytogenetics abnormalities , 121 immunohistochemical features , 120 D incidence , 119 Dacetuzumab (SGN-40) , 202Ð203 morphological features , 120 Denileukin diftitox , 218 MYC rearrangements , 119, 120 Deoxycoformycin , 225, 226 298 Index

Diffuse large B-cell lymphoma (DLBCL) Diploid transformed/non-transformed cells , 84 autologous hematopoietic stem cell Disease-modifying antirheumatic drugs transplantation (DMARDs) , 70 by age groups , 253, 254 DLBCL. See Diffuse large B-cell lymphoma chemosensitive disease , 254 (DLBCL) overall and event-free survival , Double hit DLBCL , 174 253Ð254 prognostic scores , 252 relapsed and refractory disease , 255 E rituximab regimen , 253 EATL. See Enteropathy-associated T-cell B-cell receptor , 177 lymphoma (EATL) BCL-6 expression , 40 EBV. See Epstein-Barr virus (EBV) bortezomib role , 176Ð177 Em -myc model , 90 c-MYC expression , 41, 174 Enteropathy-associated T-cell lymphoma Epstein-Barr virus (EBV) , 51 (EATL) gene dysregulation , 40 autologous hematopoietic stem cell heat shock protein inhibitors , 179 transplantation , 261Ð262 HIV-associated lymphomas CHOP , 229 clinical outcomes , 155 description , 228 incidence , 155 laparotomy , 229 post-HAART era regimens , Enzastaurin , 226 158Ð159 Epratuzumab , 182, 199Ð200 pre-HAART era regimens , 156, 157 Epstein-Barr virus (EBV) prognostic indicators , 156Ð159 anti-CD30 , 57 , 181 antiviral therapy , 57 mammalian target of rapamycin cytotoxic T-cells therapy , 56, 57 inhibitors , 180 description , 48 MGCD0103 inhibitor , 181 HIV lymphomagenesis , 37Ð39 monoclonal antibodies , 182, 183 latency patterns , 49 morphologic variants , 28Ð29 latent infection types , 48, 49 PKC inhibitors , 178 lymphoproliferative disorders prognostic factors Burkitt lymphoma , 49Ð51 ALK-positive , 127 classical Hodgkin lymphoma , 51Ð53 with chronic in fl ammation , 126 diffuse large B-cell lymphoma , 51 EBV positive, of elderly , 125 immunode fi ciency-related , 54Ð56 HHV8-associated multicentric NK/T-cell , 53 Castleman disease , 127 lytic vs. latent cycle , 48 intravascular , 126Ð127 primary infection , 48 not otherwise speci fi ed (NOS) therapeutic targets , 56Ð57 clinical features , 123 Extracavitary primary effusion lymphoma , 32 cytogenetic and oncogenetic Extranodal natural killer/T-cell lymphoma , abnormalities , 123Ð124 146Ð147 histological features , 122 immunophenotypical features , 122, 123 F incidence , 121 Feeder layer cell culture , 86 primary cutaneous, leg type , 125 Follicular lymphoma (FL) primary large B-cell lymphoma, autologous hematopoietic stem cell CNS , 124Ð125 transplantation primary mediastinal (thymic) , 126 CUP trial , 249 T-cell/histiocyte-rich large B-cell cyclophosphamide/TBI regimen , 248 lymphoma , 124 front-line treatment , 248Ð249 of salivary gland , 29 randomized trials , 249Ð252 subtypes of , 174Ð175 prognostic factors Syk inhibitors , 177 clinical features , 113Ð114 Index 299

cytogenetic abnormalities , 114 peripheral T-cell lymphomas description , 111 (see Peripheral T-cell histological features , 111Ð112 lymphomas (PTCLs)) immunophenotypical features , 112 schematic representation , 270 incidence , 111 therapeutic rationale , 269 on left hematoxylin and eosin stained Hemophagocytic syndrome , 229 slide , 112, 113 Hepatitis C virus (HCV) , 68Ð69 oncogenetic abnormalities , 114 Hepatosplenic T-cell lymphoma , 147 transformation of , 114Ð115 HHV8-associated multicentric Castleman Follicular Lymphoma International Prognostic disease , 127 Index , 113Ð114 HHV8 plasmablastic lymphomas , 31 Forodesine , 226 High-dose therapy and autologous stem cell transplant (HDT-ASCT), PTCL consolidation in CR1/PR1 , 285Ð287 G salvage vs. upfront setting , 283Ð285 , 183, 203Ð204 upfront setting , 285 Gamma herpesviruses , 37Ð39 High-grade lymphoma, stem cell Genetically engineered mice (GEM) models transplantation , 241 advantages , 91 Highly active antiretroviral therapy (HAART) , B-cell lymphoma , 90 25, 26, 36, 154Ð165, 268, 269, development of , 89 271Ð274 disadvantages , 91 Histone deacetylase inhibitors , 180 E m -myc model , 90 belinostat , 224 genetic pro fi le , 88, 89 clinical pathways , 223 MCL , 90, 91 description , 223 Germinal center B-cell (GCB) lymphomas , MGCD0103 , 181 174, 175 panobinostat , 181 GlycoMab¨ technology , 197 pralatrexate , 224Ð225 Graft versus lymphoma (GVL) effect , 288 romidepsin agent , 224 vorinostat agent , 223Ð224 HIV-associated lymphomas H Burkitt/Burkitt-like lymphoma , 159Ð160 Hans algorithm , 122, 123 classi fi cation of , 154 Hashimoto thyroiditis , 73 conditioning , 274 hBU12-vcMMAE , 205 diffuse large B-cell lymphoma , 155Ð159 Heat shock protein (HSP) inhibitors , 179 epidemiology , 154 Helicobacter pylori , 65Ð66 full-dose standard chemotherapy , 268 Hematopoiesis , 12, 13 hematopoeitic progenitors , 273Ð274 Hematopoietic stem cells (HSC) hematopoietic stem cell transplantation cell surface marker expression , 13 allogeneic , 272Ð273 common lymphoid precursors , 14 autologous , 269, 271Ð272 de fi nition , 12 description , 269 identi fi cation of , 13 high-dose chemotherapy/ multipotential progenitor cells , 13Ð14 radiotherapy , 269 single-cell level analysis , 13 schematic representation , 270 stochastic differences , 13 therapeutic rationale , 269 transcription factors , 13 high-risk features , 268 Hematopoietic stem cell transplantation immune reconstitution , 274Ð275 (HSCT). See also non-relapse mortality , 271, 272 HIV-associated lymphomas peripheral T-cell lymphoma , 164Ð165 allogeneic , 272Ð273 plasmablastic lymphoma , 162Ð163 autologous , 269, 271Ð272 posttransplant engraftment , 274Ð275 description , 269 primary CNS lymphoma , 161Ð162 high-dose chemotherapy/ primary effusion lymphoma , 163Ð164 radiotherapy , 269 rituximab addition , 268 300 Index

HIV lymphomagenesis Immunoblastic lymphoma (IBL) , 28Ð29 AIDS-related lymphomas Immunode fi ciency-related lymphoproliferative Burkitt lymphoma , 26, 28 disorders CD4+ cell counts , 26 acquired immunode fi ciency syndrome , classic primary effusion lymphoma , 54Ð55 31, 32 congenital immunode fi ciency , 54 classi fi cation , 24Ð25 human immunode fi ciency , 54Ð55 description , 24 iatrogenic immunode fi ciency , 55 diffuse large B-cell lymphoma , 28Ð29 posttransplant lymphoproliferative epidemiology , 25 disorders , 55Ð56 extracavitary (solid) primary effusion Immunomodulatory drugs (IMiDs) , 181 lymphoma , 32 Immunotoxins, anti-CD22 Hodgkin lymphoma , 33Ð34 BL-22 , 200 low-grade non-Hodgkin lymphoma , 33 moxetumomab pasudotox , 200Ð201 mature T-cell non-Hodgkin Indolent non-Hodgkin lymphoma lymphoma , 33 monoclonal antibodies , 193 plasmablastic lymphoma , 29Ð31 anti-CD19 , 205Ð206 vs. plasmacellular differentiation, 26, 27 anti-CD20 (see Anti-CD20 monoclonal polymorphic lymphoproliferative antibodies) disorder , 32Ð33 anti-CD22 , 199Ð201 B cells , 35, 36 anti-CD37 , 204 gamma herpesviruses anti-CD40 , 202Ð203 EBV coinfection , 37, 39 anti-CD74 , 201Ð202 HHV8 coinfection , 37, 39Ð40 anti-CD80 , 203Ð204 lymphoproliferative disorders , 38 anti-human leukocyte antigen-DR , 201 gene dysregulation anti-T cell , 207Ð208 BCL-6 expression , 40Ð41 B-cell surface antigen targets , 192, 194 c-MYC expression , 41 clinical trials , 192, 195 DLBCL , 40 TRAIL receptors , 206Ð207 p53 mutation , 41 Innate immune responses , 11 HIV infection , 36Ð37 Inotuzumab ozogamicin , 183, 200 immune dysregulation , 37 International Prognostic Index (IPI) , NHL , 23, 24 26, 102Ð103 risk factors , 34Ð35 adult T-cell leukemia/lymphoma , 145 Hodgkin lymphoma , 33Ð34 anaplastic large cell lymphoma , 146 HSCT. See Hematopoietic stem cell angioimmunoblastic lymphoma , 144 transplantation (HSCT) extranodal natural killer/T-cell lymphoma , Human herpes virus 4. See Epstein-Barr 146, 147 virus (EBV) HIV-associated lymphomas , 268 Human immunode fi ciency virus (HIV) , 54Ð55 . peripheral T-cell lymphoma , 142 See also AIDS-related peripheral T-cell lymphoma not otherwise lymphomas (ARL); HIV- speci fi ed , 142Ð143 associated lymphomas; HIV IPI. See International Prognostic Index (IPI) lymphomagenesis Human T-cell leukemia virus-1-associated T-cell leukemia/lymphoma , K 227Ð228 Kaposi sarcoma herpesvirus (KSHV) , 37 Human tumor xenograft , 91Ð93 Ki-67 proliferation index , 26, 108, 109, 112, 115, 118, 120, 122

I Iatrogenic immunode fi ciency-associated L lymphoproliferative disorders , 55 Large-cell lymphoma, stem cell IBL. See Immunoblastic lymphoma (IBL) transplantation , 240 Immune dysregulation , 37 Lenalidomide , 181, 206, 225 Index 301

Lexatumumab , 207 prognostic factors Low-grade lymphoma clinical features , 110Ð111 non-Hodgkin lymphoma , 33 cytogenetic abnormalities , 109Ð110 stem cell transplantation , 239Ð240 description , 107 Lucatumumab (HCD122) , 202 histopathological features , 108 Lymphocytes , 12 immunophenotypic features , 108Ð109 B lymphocytes , 14Ð16 oncogenetic abnormalities , 109Ð110 T lymphocytes , 16Ð19 peripheral blood involvement , 108, 109 Lymphoma p53 expression by blastoid variant , clinical outcome , 82 109, 110 NHL , 82 stem cell transplantation , 241Ð242 preclinical animal models transgenic mouse models , 90, 91 advantages , 91 , 206 categories , 87 Marginal zone type lymphomas, Daudi cells , 87 prognostic factors development , 87 extranodal , 115Ð116 disadvantages , 91 nodal , 116 FC-CD40L vaccination , 88 splenic , 117 genetically engineered mice , 88Ð91 Mature T-cell non-Hodgkin humanized mice , 93Ð94 lymphoma , 33 human tumor xenograft , 91Ð93 MCL. See Mantle cell lymphoma (MCL) MCL , 90, 91 , 202 SCID , 87, 92 Monoclonal antibodies (mAbs) syngeneic models , 88, 89 antibody characteristics , 193 in vitro preclinical models , 82 anti-CD19 cell culture experiments , 83 blinatumomab , 205 cell lines , 83Ð86 hBU12-vcMMAE , 205 normal lymphocytes , 84, 86Ð87 XmAb5574 , 206 primary tumor cells , 83 anti-CD20 (see Anti-CD20 stem cell , 83Ð84 monoclonal antibodies) Lymphoplasmacytic lymphoma, anti-CD22 prognostic factors epratuzumab , 199Ð200 clinical features , 118Ð119 immunotoxins , 200Ð201 histological features , 118 inotuzumab ozogamicin , 200 immunophenotypical features , 118 anti-CD37 , 204 molecular and cytogenetic anti-CD40 abnormalities , 119 dacetuzumab , 202Ð203 Lymphoproliferative disorders, EBV lucatumumab , 202 Burkitt lymphoma , 49Ð51 XmAbCD40 , 203 classical Hodgkin lymphoma , 51Ð53 anti-CD74 , 201Ð202 diffuse large B-cell lymphoma , 51 anti-CD80 , 203Ð204 immunode fi ciency-related , 54Ð56 anti-human leukocyte antigen-DR , 201 NK/T-cell , 53 anti-T cell , 207Ð208 B-cell surface antigen targets , 192, 194 M clinical trials , 192, 195 mAbs. See Monoclonal antibodies (mAbs) MAb 37.1 and MAb 37.2 , 204 Mammalian target of rapamycin (mTOR) TRAIL receptors inhibitors , 179Ð180 conatumumab , 207 Mantle cell lymphoma (MCL) description , 206 autologous hematopoietic stem cell , 207 transplantation , 255Ð256 mapatumumab , 206 cyclin D1 deregulation , 90, 91 Moxetumomab pasudotox , 200Ð201 302 Index

Mucosa-associated lymphoid tissue (MALT) anaplastic large cell lymphoma , 145Ð146 lymphomas , 72, 73 angioimmunoblastic T-cell lymphoma , 144 C. psittaci , 66, 67 ARL , 33 extranodal marginal zone lymphoma of autologous hematopoietic stem cell clinical features , 116 transplantation cytogenetic abnormalities , 116 salvage studies , 258, 260 description , 115 up-front studies , 258, 259 histological and immunophenotypical autologous transplant features , 115 in salvage setting , 282Ð283 H. pylori , 65, 66 in upfront setting , 283Ð287 Mycosis fungoides , 21 , 219, 225 chemotherapy for , 280Ð281 CHOP-based regimens , 217Ð219 N description , 141 Natural killer (NK) cells even-free survival , 216, 217 activation of , 20 evidence-based treatment approach , 232 description , 19 extranodal natural killer/T-cell lymphoma , development in bone marrow sites , 19, 20 146Ð147 non-bone marrow sites , 20 gemcitabine-based regimens , 219Ð220 Natural killer/T-cell lymphoma (NKTCL) , HDT-ASCT 146 . See also Extranodal natural consolidation in CR1/PR1 , 285Ð287 killer/T-cell lymphoma salvage vs. upfront setting , 283Ð285 Nodal marginal zone lymphoma , 116 upfront setting , 285 Non-relapse mortality (NRM) , 271, 272 hepatosplenic T-cell lymphoma , 147 Non-transformed cells , 84Ð86 HIV-associated lymphomas Nucleoside analogs , 225, 226 prognostic factors , 165 risks of , 164Ð165 WHO classi fi cation , 165 O incidence , 141Ð142 , 182 International Prognostic Index , 142 Ocrelizumab , 194, 195 not otherwise speci fi ed , 142Ð143 Ocular adnexal lymphomas (OAL) , 66Ð68 overall survival of patients , 213, 214 Ofatumumab , 182, 197 standard fi rst-line therapy , 216Ð217 subcutaneous panniculitis T-cell lymphoma , 147 P T-cell large granular lymphocytic PCGD-TCL. See Primary cutaneous leukemia , 147 gamma/delta T-cell lymphoma transplantation , 220, 231Ð232 (PCGD-TCL) WHO classi fi cation , 213, 215 PCNSL. See Primary central nervous system PI3 kinase (PI3K) inhibitors , 226 lymphoma (PCNSL) PKC inhibitors , 178 PEL. See Primary effusion lymphoma (PEL) Plasmablastic lymphoma (PBL) Pentostatin. See Deoxycoformycin extranodal sites of , 29 Peripheral T-cell lymphomas (PTCLs) HHV8 , 31 adult T-cell leukemia/lymphoma , HIV-associated lymphomas , 162Ð163 144Ð145 morphologic subgroups , 30 agents used in , 221, 222 of retroperitoneum , 30 allogeneic transplant p53 mutation , 41 graft versus lymphoma effect , 288 Polymorphic lymphoproliferative disorder , heterogeneous conditioning , 289Ð290 32Ð33 myeloablative conditioning , 288Ð289 Posttransplant lymphoproliferative disorders prospective analysis , 290Ð291 (PTLD) , 55Ð56 Index 303

Pralatrexate , 224Ð225 Stem cell transplantation Primary central nervous system lymphoma anti-angiogenesis agents , 243 (PCNSL) , 24, 161Ð162 central nervous system lymphoma , 242 Primary cutaneous gamma/delta T-cell elderly patients , 242 lymphoma (PCGD-TCL) , high-grade lymphoma , 241 229Ð231 immunomodulators , 243 Primary cutaneous T-cell lymphomas, 262Ð263 large-cell lymphoma , 240 Primary effusion lymphoma (PEL) low-grade lymphoma , 239Ð240 classic variant of , 31 mantle cell lymphoma , 241Ð242 CT scan , 31, 32 Subcutaneous panniculitis-T-cell lymphoma gene expression pro fi ling , 31 (SPTCL), 147, 229Ð231 HIV-associated lymphomas , 163Ð164 Syk inhibitors , 177 Proteasome inhibitors , 176Ð177, 226 Systemic lupus eryhtematosus (SLE) , 71 PTCLs. See Peripheral T-cell lymphomas (PTCLs) T T-cell large granular lymphocytic leukemia , R 147 Rai-Sawitsky system , 105, 106 T-cell lymphomas Rheumatoid arthritis (RA) ACVBP regimen , 217 anti-TNF therapy , 71 CHOP-based regimens , 217Ð219 disease-modifying antirheumatic drug cutaneous group of , 215Ð216 effects , 70 extranodal , 214 high in fl ammatory activity , 70 histone deacetylase inhibitors , 223Ð225 risk ratio , 69Ð70 immunomodulators , 225 immunosuppressants , 225 leukemic group , 214, 215 S monoclonal antibodies and Severe combined immunode fi ciency immunoconjugates (SCID) model , 222, 223 advantages , 87 CD30 receptor , 221, 223 mice models , 92 LMB-2 , 221 ofatumumab, antitumor activity of , 93 SGN-35 , 221, 222 rituximab , 92, 93 siplizumab , 221 Sézary syndrome (SS) , 208 zanolimumab , 221 SGN-35 , 221, 222 nodal , 214 SGN-40 , 183 nucleoside analogs , 225Ð226 Shimoyama classi fication , 144 peripheral (see Peripheral T-cell Siplizumab , 207Ð208, 221 lymphomas (PTCLs)) Sjogren syndrome (SS) pralatrexate , 224Ð225 benign myoepithlial sialadenitis lesions , 72 proteasome inhibitors , 226 clinical manifestations , 71 response rates for therapies , 221, 223 description , 71 rituximab , 219, 221, 225 vs. HCV-associated B-cell lymphoma, 72Ð73 signaling inhibitors , 226 risk estimates , 71 treatment Small modular immunopharmaceutical EATL , 228Ð229 (SMIPTª) , 199 HTLV-1-associated , 227Ð228 Solid PEL , 32 NK/T-cell lymphoma , 227 Splenic B-cell lymphoma/leukemia , 117 SPTCL , 229Ð231 Splenic marginal zone lymphoma (SMZL) , 117 T lymphocytes , 16Ð19 SPTCL. See Subcutaneous panniculitis-T-cell TRAIL receptors. See Tumor necrosis lymphoma (SPTCL) factor-related apoptosis-inducing Standard fi rst-line therapy, PTCL , 216Ð217 ligand (TRAIL) receptors 304 Index

Transgenic mice models. See Genetically V engineered mice (GEM) Veltuzumab , 182, 196 models Vorinostat , 180, 207, 223, 224 TRU-016 , 204 TRU-015 SMIP molecule , 199 -related apoptosis- W inducing ligand (TRAIL) Warburg effect , 175 receptors conatumumab , 207 description , 206 X lexatumumab , 207 XmAb5574 , 206 mapatumumab , 206 XmAbCD40 , 203

U Z Umbilical cord blood transplantation , Zanolimumab , 208, 221 242Ð243 Zidovudine , 228